Buspirone augmentation of fluoxetine in obsessive-compulsive disorder

P J Markovitz; S J Stagno; J R Calabrese

doi:10.1176/ajp.147.6.798

Buspirone augmentation of fluoxetine in obsessive-compulsive disorder

Am J Psychiatry. 1990 Jun;147(6):798-800. doi: 10.1176/ajp.147.6.798.

Authors

P J Markovitz¹, S J Stagno, J R Calabrese

Affiliation

¹ Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH.

PMID: 2188516
DOI: 10.1176/ajp.147.6.798

Abstract

Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.

Publication types

Clinical Trial

MeSH terms

Adult
Buspirone / therapeutic use*
Clinical Trials as Topic
Drug Therapy, Combination
Female
Fluoxetine / therapeutic use*
Humans
Male
Obsessive-Compulsive Disorder / drug therapy*
Obsessive-Compulsive Disorder / psychology
Prospective Studies
Receptors, Serotonin / drug effects

Substances

Receptors, Serotonin
Fluoxetine
Buspirone